Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Allergic Bronchopulmonary Aspergillosis
NCT04442269Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2020
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in allergic bronchopulmonary aspergillosis (ABPA) comparing Dupilumab with Placebo (2 arms). Primary endpoint: Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second at 24 weeks. Started Sep 2020; status: completed.
02
Drugs
03
Conditions
allergic bronchopulmonary aspergillosis (ABPA)
Beyond the preview
Go deeper on NCT04442269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04442269.